gamma-aminobutyric acid has been researched along with Herpes Zoster in 69 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Herpes Zoster: An acute infectious, usually self-limited, disease believed to represent activation of latent varicella-zoster virus (HERPESVIRUS 3, HUMAN) in those who have been rendered partially immune after a previous attack of CHICKENPOX. It involves the SENSORY GANGLIA and their areas of innervation and is characterized by severe neuralgic pain along the distribution of the affected nerve and crops of clustered vesicles over the area. (From Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized, double-blind, placebo-controlled, two-session crossover study the effect of a single oral dose of pregabalin (150 mg) on pain and allodynia was evaluated in 8 subjects with herpes zoster." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Compared to an earlier study of gabapentin 900 mg for acute zoster pain and allodynia that followed a nearly identical protocol, pregabalin had a similar effect on pain and was well tolerated, with no difference from placebo on sleepiness." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "The effect of pregabalin on acute herpes zoster pain has not been previously evaluated." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Over 6 hours of observation, pain decreased by a mean of 33% with pregabalin and 14% with placebo (p < 0." | 9.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "The study did not prove any statistically significant effect of pregabalin in pain relief in patients with acute zoster pain or in the onset of postherpetic neuralgia in comparison with the placebo." | 9.14 | Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence. ( Kamenik, M; Krcevski Skvarc, N, 2010) |
| "To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain." | 9.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "According with data used in this modeling in patients with NeP due to DPN and/or PHN, PGB was shown to be more cost-effective than generic gabapentin in Spain." | 9.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)." | 9.11 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 9.11 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "This randomized, double-blind, placebo-controlled crossover study measured the effect of a single dose of oral gabapentin (900 mg) on pain and allodynia associated with herpes zoster." | 9.11 | A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. ( Berry, JD; Petersen, KL, 2005) |
| "To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN)." | 9.10 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "A multicentre double blind, randomised, placebo controlled 7-week study evaluated the efficacy and safety of gabapentin 1800 or 2400 mg/day in treating postherpetic neuralgia." | 9.09 | Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. ( Maton, S; Rice, ASC, 2001) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated." | 9.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 8.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| " Search terms used were postherpetic neuralgia; zoster; gabapentin; neuropathic pain; pain; pharmacoeconomic; cost; controlled clinical trial; randomized, controlled trial; postherpetic neuralgia and gabapentin; gabapentin and pain; treatment and postherpetic neuralgia; gabapentin and age; gabapentin and gender; gabapentin and ethnicity; and gabapentin and pharmacokinetics." | 8.82 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 8.82 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash." | 8.82 | Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. ( Glanzman, RL; Stacey, BR, 2003) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 8.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 8.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 8.81 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "The frequency of PHN after untreated zoster varies widely." | 7.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| "To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster." | 7.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "The combination of gabapentin and valacyclovir administered acutely in patients with herpes zoster reduces the incidence of postherpetic neuralgia." | 7.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| " In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain." | 7.72 | Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003) |
| "Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons." | 6.84 | Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. ( Bulilete, O; González-Bals, MJ; Leiva, A; Llobera, J; Lorente, P; Roca, A; Rullán, M; Soler, A, 2017) |
| "Effects on allodynia and SF-MPQ were not significant." | 6.76 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "The model assigned untreated pain scores over 84 days." | 6.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "Pain was evaluated using a 0-10 scale." | 6.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| " Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity." | 6.71 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "Pregabalin efficaciously treated the neuropathic pain of PHN." | 6.71 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "Each gabapentin-naive subject was allocated to receive either 200 mg (100 mg, twice daily), 400 mg (100 mg, four times daily), or 600 mg (200 mg, three times daily) of gabapentin for three days." | 6.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 6.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Reductions in allodynia area and severity, and overall pain relief, were also greater with gabapentin." | 6.71 | A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. ( Berry, JD; Petersen, KL, 2005) |
| "A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo." | 6.69 | Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. ( Bernstein, P; Harden, N; Magnus-Miller, L; Rowbotham, M; Stacey, B, 1998) |
| " Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%." | 6.43 | Pregabalin: a new agent for the treatment of neuropathic pain. ( Zareba, G, 2005) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin was first approved by the FDA in 1993 as an add-on treatment for partial epileptic seizures." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Over 150 articles reviewed its use for neuropathic pain, neuritis or neuralgia of various sorts." | 6.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin displays nonlinear absorption kinetics, is minimally protein bound (< 3%), has a high mean (SD) volume of distribution (50." | 6.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| " The recommended dosage in adults is 300 mg at bedtime on day 1,300 mg BID on day 2, and 300 mg TID on day 3, titrating up as needed to 2400 to 3600 mg/d." | 6.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 6.42 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "Gabapentin was initiated at 300 mg/d and titrated to maintenance doses of 1800 to 3600 mg/d by day 12 to 24." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " It is assumed that adverse events occurring with gabapentin are dose related, their frequency and severity increasing with increasing doses." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "The aim of this study was to assess the dose dependence of adverse events with gabapentin by determining the relationship between increasing doses of gabapentin and the onset and/or worsening of adverse events in patients with PHN." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The analysis of adverse events was based on 3 distinct groups: patients who received gabapentin <1800 mg/d, those who received gabapentin >or=1800 mg/d, and those who received placebo." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The 3 most common adverse events were dizziness, somnolence, and peripheral edema." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " Dizziness and somnolence, the other most commonly occurring adverse events, were transient and did not occur more frequently or worsen with titration to >or=1800 mg/d." | 6.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 6.41 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "In a randomized, double-blind, placebo-controlled, two-session crossover study the effect of a single oral dose of pregabalin (150 mg) on pain and allodynia was evaluated in 8 subjects with herpes zoster." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Compared to an earlier study of gabapentin 900 mg for acute zoster pain and allodynia that followed a nearly identical protocol, pregabalin had a similar effect on pain and was well tolerated, with no difference from placebo on sleepiness." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "The effect of pregabalin on acute herpes zoster pain has not been previously evaluated." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| "Over 6 hours of observation, pain decreased by a mean of 33% with pregabalin and 14% with placebo (p < 0." | 5.15 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| " Up to estimated 336 patients (interim analyses) with acute herpes zoster pain (VAS > 30 mm) will be randomised to one of three groups (a) semi-standardised acupuncture (168 patients); (b) gabapentine with individualised dosage between 900-3600 mg/d (84 patients); (c) sham laser acupuncture." | 5.14 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "This study is the first large-scale randomised placebo controlled trial to evaluate the efficacy of acupuncture compared to gabapentine and sham treatment and will provide valuable new information about the clinical and physiological effects of acupuncture and gabapentine in the treatment of acute herpes zoster pain." | 5.14 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "The study did not prove any statistically significant effect of pregabalin in pain relief in patients with acute zoster pain or in the onset of postherpetic neuralgia in comparison with the placebo." | 5.14 | Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence. ( Kamenik, M; Krcevski Skvarc, N, 2010) |
| "To estimate the cost-effectiveness of branded pregabalin (PGB) versus generic gabapentin (GBP) in patients with neuropathic pain (NeP) due to painful diabetic polyneuropathy (DPN) or post-herpetic neuralgia (PHN) in Spain." | 5.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "According with data used in this modeling in patients with NeP due to DPN and/or PHN, PGB was shown to be more cost-effective than generic gabapentin in Spain." | 5.12 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "This study was designed to assess the efficacy and safety of pregabalin-a novel alpha(2)-delta ligand with analgesic, anxiolytic, and anticonvulsant activity-for treating neuropathic pain in patients with post-herpetic neuralgia (PHN)." | 5.11 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 5.11 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "This randomized, double-blind, placebo-controlled crossover study measured the effect of a single dose of oral gabapentin (900 mg) on pain and allodynia associated with herpes zoster." | 5.11 | A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. ( Berry, JD; Petersen, KL, 2005) |
| "To evaluate the efficacy and safety of pregabalin in the treatment of postherpetic neuralgia (PHN)." | 5.10 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "A multicentre double blind, randomised, placebo controlled 7-week study evaluated the efficacy and safety of gabapentin 1800 or 2400 mg/day in treating postherpetic neuralgia." | 5.09 | Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. ( Maton, S; Rice, ASC, 2001) |
| "A large case series of patients with centrally mediated pain, peripherally mediated pain, migraine, and tremor were treated in an open-label study with gabapentin (maximum of 2,700 mg/day)." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin offers an effective, safe alternative therapy or co-therapy for the listed painful conditions and tremor; it does not affect the metabolism of other medications and is well tolerated." | 5.08 | Gabapentin for treatment of pain and tremor: a large case series. ( Merren, MD, 1998) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 4.82 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| " Search terms used were postherpetic neuralgia; zoster; gabapentin; neuropathic pain; pain; pharmacoeconomic; cost; controlled clinical trial; randomized, controlled trial; postherpetic neuralgia and gabapentin; gabapentin and pain; treatment and postherpetic neuralgia; gabapentin and age; gabapentin and gender; gabapentin and ethnicity; and gabapentin and pharmacokinetics." | 4.82 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 4.82 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "The literature search identified 2 published studies of the efficacy of gabapentin in a total of 563 patients with PHN that had persisted for at least 3 months after the healing of herpes zoster rash." | 4.82 | Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies. ( Glanzman, RL; Stacey, BR, 2003) |
| "In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d." | 4.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 4.82 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 4.81 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "The frequency of PHN after untreated zoster varies widely." | 3.79 | Postherpetic neuralgia: role of gabapentin and other treatment modalities. ( Beydoun, A, 1999) |
| " Gabapentin has been successfully used to treat cutaneous pain and pruritus in a variety of conditions." | 3.77 | A case of post-herpetic itch resolved with gabapentin. ( Jagdeo, J; Kroshinsky, D, 2011) |
| "To evaluate the efficacy of treatment with gabapentin plus valacyclovir hydrochloride for the prevention of postherpetic neuralgia in patients with acute herpes zoster." | 3.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| "The combination of gabapentin and valacyclovir administered acutely in patients with herpes zoster reduces the incidence of postherpetic neuralgia." | 3.77 | Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. ( Digiorgio, C; Grady, J; Haitz, K; Lapolla, W; Lu, W; Magel, G; Mendoza, N; Tyring, S, 2011) |
| " In order to avoid drug interactions as well as adverse effects of carbamazepine in myasthenia gravis, gabapentin was chosen for the treatment of neuropathic pain." | 3.72 | Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin. ( Beuche, W; Scheschonka, A, 2003) |
| "Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons." | 2.84 | Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial. ( Bulilete, O; González-Bals, MJ; Leiva, A; Llobera, J; Lorente, P; Roca, A; Rullán, M; Soler, A, 2017) |
| "Effects on allodynia and SF-MPQ were not significant." | 2.76 | Effect of a single dose of pregabalin on herpes zoster pain. ( Jensen-Dahm, C; Petersen, KL; Reda, H; Rowbotham, MC, 2011) |
| " Up to estimated 336 patients (interim analyses) with acute herpes zoster pain (VAS > 30 mm) will be randomised to one of three groups (a) semi-standardised acupuncture (168 patients); (b) gabapentine with individualised dosage between 900-3600 mg/d (84 patients); (c) sham laser acupuncture." | 2.74 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "Acute herpes zoster is a prevalent condition." | 2.74 | Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial. ( Fleckenstein, J; Hoffrogge, P; Irnich, D; Kramer, S; Lang, PM; Lehmeyer, L; Mansmann, U; Pfab, F; Ring, J; Schober, GM; Schotten, KJ; Thoma, S; Weisenseel, P, 2009) |
| "The model assigned untreated pain scores over 84 days." | 2.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| "Pain was evaluated using a 0-10 scale." | 2.73 | Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia. ( Díaz, S; Dukes, E; Rejas, J; Rodríguez, MJ; Vera-Llonch, M, 2007) |
| " Given the maximal dosage studied, pregabalin had acceptable tolerability compared to placebo despite a greater incidence of side effects, which were generally mild to moderate in intensity." | 2.71 | Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. ( Bockbrader, H; Corbin, AE; Dworkin, RH; Garofalo, EA; LaMoreaux, L; Poole, RM; Sharma, U; Young, JP, 2003) |
| "Pregabalin efficaciously treated the neuropathic pain of PHN." | 2.71 | Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. ( Cherry, DA; Gálvez, R; Jacquot, F; Maisonobe, P; Sabatowski, R; Versavel, M; Vincent, E, 2004) |
| "Oxcarbazepine appears to be a promising alternative monotherapeutic approach for patients affected by PHN." | 2.71 | Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005) |
| "Oxcarbazepine was effective from the first week of treatment." | 2.71 | Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005) |
| "Pain was assessed using a visual analog scale (VAS)." | 2.71 | Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin. ( Auletta, C; Brogi, A; Brogi, F; Criscuolo, S; Lippi, S, 2005) |
| "Each gabapentin-naive subject was allocated to receive either 200 mg (100 mg, twice daily), 400 mg (100 mg, four times daily), or 600 mg (200 mg, three times daily) of gabapentin for three days." | 2.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Gabapentin has been shown to provide pain relief for post-herpetic neuralgia at dosage of 1200 to 2400 mg/day." | 2.71 | Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study. ( Jean, WH; Mok, MS; Sun, WZ; Wu, CC, 2005) |
| "Reductions in allodynia area and severity, and overall pain relief, were also greater with gabapentin." | 2.71 | A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster. ( Berry, JD; Petersen, KL, 2005) |
| "A 4-week titration period to a maximum dosage of 3600 mg/d of gabapentin or matching placebo." | 2.69 | Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. ( Bernstein, P; Harden, N; Magnus-Miller, L; Rowbotham, M; Stacey, B, 1998) |
| "Once established, postherpetic neuralgia is particularly difficult to treat, and is often resistant to conventional analgesics." | 2.47 | [Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia]. ( Takasaki, I, 2011) |
| " Peak plasma levels occur approximately 1 hour after oral doses and oral bioavailability is about 90%." | 2.43 | Pregabalin: a new agent for the treatment of neuropathic pain. ( Zareba, G, 2005) |
| "Gabapentin is a very promising medication in the treatment of post-herpetic neuralgia and pain." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin was first approved by the FDA in 1993 as an add-on treatment for partial epileptic seizures." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Over 150 articles reviewed its use for neuropathic pain, neuritis or neuralgia of various sorts." | 2.42 | The role of gabapentin in treating diseases with cutaneous manifestations and pain. ( Scheinfeld, N, 2003) |
| "Gabapentin displays nonlinear absorption kinetics, is minimally protein bound (< 3%), has a high mean (SD) volume of distribution (50." | 2.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| " The recommended dosage in adults is 300 mg at bedtime on day 1,300 mg BID on day 2, and 300 mg TID on day 3, titrating up as needed to 2400 to 3600 mg/d." | 2.42 | The use of gabapentin for the treatment of postherpetic neuralgia. ( Kennedy, DH; Singh, D, 2003) |
| "Gabapentin is a structural analogue of the neurotransmitter gamma-aminobutyric acid (GABA) approved for use in adults with postherpetic neuralgia." | 2.42 | Gabapentin: in postherpetic neuralgia. ( Curran, MP; Wagstaff, AJ, 2003) |
| "Managing patients with chronic neuropathic pain is a common clinical challenge due to variability in individual symptoms, mechanisms, and treatment responses." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "Diagnosis and management of neuropathic pain syndromes is challenging." | 2.42 | Diagnosis and management of neuropathic pain: a balanced approach to treatment. ( Nicholson, BD, 2003) |
| "The most common risk factor for shingles and its potential sequela, PHN, is advanced age." | 2.42 | Post-herpetic neuralgia case study: optimizing pain control. ( Baron, R, 2004) |
| "Gabapentin was initiated at 300 mg/d and titrated to maintenance doses of 1800 to 3600 mg/d by day 12 to 24." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Gabapentin has been shown to be well tolerated and effective in the management of the pain associated with postherpetic neuralgia (PHN)." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " It is assumed that adverse events occurring with gabapentin are dose related, their frequency and severity increasing with increasing doses." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "The aim of this study was to assess the dose dependence of adverse events with gabapentin by determining the relationship between increasing doses of gabapentin and the onset and/or worsening of adverse events in patients with PHN." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The analysis of adverse events was based on 3 distinct groups: patients who received gabapentin <1800 mg/d, those who received gabapentin >or=1800 mg/d, and those who received placebo." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " The 3 most common adverse events were dizziness, somnolence, and peripheral edema." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| " Dizziness and somnolence, the other most commonly occurring adverse events, were transient and did not occur more frequently or worsen with titration to >or=1800 mg/d." | 2.42 | Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia. ( Huang, S; Parsons, B; Tive, L, 2004) |
| "Trigeminal neuralgia is a unique neuropathic pain disorder with a specific therapy." | 2.42 | Management issues of neuropathic trigeminal pain from a medical perspective. ( Watson, CP, 2004) |
| "Gabapentin, which has been approved for add-on therapy of focal seizures, is increasingly used for treatment of neuropathic pain." | 2.41 | [Gabapentin therapy for pain]. ( Block, F, 2001) |
| "In this study orofacial pain was induced by injecting male rats with the human VZV." | 1.72 | Neurexin 3α in the Central Amygdala has a Role in Orofacial Varicella Zoster Pain. ( Hornung, R; Kinchington, PR; Kramer, PR; Umorin, M, 2022) |
| "Gabapentin has been successfully used to treat cutaneous pain and pruritus in a variety of conditions." | 1.37 | A case of post-herpetic itch resolved with gabapentin. ( Jagdeo, J; Kroshinsky, D, 2011) |
| "Herpes zoster is a skin disease encountered commonly in dermatologic practice." | 1.37 | A case of post-herpetic itch resolved with gabapentin. ( Jagdeo, J; Kroshinsky, D, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (10.14) | 18.2507 |
| 2000's | 43 (62.32) | 29.6817 |
| 2010's | 17 (24.64) | 24.3611 |
| 2020's | 2 (2.90) | 2.80 |
| Authors | Studies |
|---|---|
| Kramer, PR | 1 |
| Umorin, M | 1 |
| Hornung, R | 1 |
| Kinchington, PR | 2 |
| Sadaeng, W | 1 |
| Márta, K | 1 |
| Mátrai, P | 1 |
| Hegyi, P | 1 |
| Tóth, B | 1 |
| Németh, B | 1 |
| Czumbel, LM | 1 |
| Sang-Ngoen, T | 1 |
| Gyöngyi, Z | 1 |
| Varga, G | 1 |
| Révész, P | 1 |
| Szanyi, I | 1 |
| Karádi, K | 1 |
| Gerber, G | 1 |
| Migita, T | 1 |
| Johnson, RW | 2 |
| Rice, AS | 1 |
| Lee, EG | 1 |
| Lee, HJ | 1 |
| Hyun, DJ | 1 |
| Min, K | 1 |
| Kim, DH | 1 |
| Yoon, MS | 1 |
| Rullán, M | 1 |
| Bulilete, O | 1 |
| Leiva, A | 1 |
| Soler, A | 1 |
| Roca, A | 1 |
| González-Bals, MJ | 1 |
| Lorente, P | 1 |
| Llobera, J | 1 |
| De Smedt, RH | 1 |
| Jaarsma, T | 1 |
| van den Broek, SA | 1 |
| Haaijer-Ruskamp, FM | 1 |
| Einarsdottir, S | 1 |
| Björnsson, E | 1 |
| Dworkin, RH | 4 |
| Barbano, RL | 1 |
| Tyring, SK | 2 |
| Betts, RF | 1 |
| McDermott, MP | 1 |
| Pennella-Vaughan, J | 1 |
| Bennett, GJ | 1 |
| Berber, E | 1 |
| Gnann, JW | 1 |
| Irvine, C | 1 |
| Kamp, C | 1 |
| Kieburtz, K | 1 |
| Max, MB | 1 |
| Schmader, KE | 2 |
| Fleckenstein, J | 1 |
| Kramer, S | 1 |
| Hoffrogge, P | 1 |
| Thoma, S | 1 |
| Lang, PM | 1 |
| Lehmeyer, L | 1 |
| Schober, GM | 1 |
| Pfab, F | 1 |
| Ring, J | 1 |
| Weisenseel, P | 1 |
| Schotten, KJ | 1 |
| Mansmann, U | 1 |
| Irnich, D | 1 |
| Krcevski Skvarc, N | 1 |
| Kamenik, M | 1 |
| Sheen, VL | 1 |
| Ohaegbulam, C | 1 |
| Rencus, T | 1 |
| Tandon, D | 1 |
| Ochi, Y | 1 |
| Harada, T | 1 |
| Kikuchi, C | 1 |
| Arakawa, A | 1 |
| Ong, OL | 1 |
| Churchyard, AC | 1 |
| New, PW | 1 |
| Jagdeo, J | 1 |
| Kroshinsky, D | 1 |
| Micucci, CJ | 1 |
| Nease, EK | 1 |
| Tuten, HR | 1 |
| Takasaki, I | 1 |
| Jensen-Dahm, C | 1 |
| Rowbotham, MC | 1 |
| Reda, H | 1 |
| Petersen, KL | 2 |
| Lapolla, W | 1 |
| Digiorgio, C | 1 |
| Haitz, K | 1 |
| Magel, G | 1 |
| Mendoza, N | 1 |
| Grady, J | 1 |
| Lu, W | 1 |
| Tyring, S | 1 |
| Green, CB | 1 |
| Stratman, EJ | 1 |
| Fett, N | 1 |
| Chen, WH | 1 |
| Li, TH | 1 |
| Lee, LH | 1 |
| Huang, CC | 1 |
| Thakur, R | 1 |
| Philip, AG | 1 |
| Corbin, AE | 1 |
| Young, JP | 1 |
| Sharma, U | 1 |
| LaMoreaux, L | 1 |
| Bockbrader, H | 1 |
| Garofalo, EA | 1 |
| Poole, RM | 1 |
| Lovitt, S | 1 |
| Scheinfeld, N | 1 |
| Singh, D | 1 |
| Kennedy, DH | 1 |
| Scheschonka, A | 1 |
| Beuche, W | 1 |
| Curran, MP | 1 |
| Wagstaff, AJ | 1 |
| Stacey, BR | 2 |
| Junker, U | 1 |
| Brunnmüller, U | 1 |
| Glanzman, RL | 1 |
| Berger, A | 1 |
| Dukes, E | 2 |
| McCarberg, B | 1 |
| Liss, M | 1 |
| Oster, G | 1 |
| Nicholson, BD | 1 |
| Baron, R | 1 |
| Sabatowski, R | 1 |
| Gálvez, R | 1 |
| Cherry, DA | 1 |
| Jacquot, F | 1 |
| Vincent, E | 1 |
| Maisonobe, P | 1 |
| Versavel, M | 1 |
| Lim, LS | 1 |
| Takahashi, PY | 1 |
| Dubinsky, RM | 1 |
| Kabbani, H | 1 |
| El-Chami, Z | 1 |
| Boutwell, C | 1 |
| Ali, H | 1 |
| Sra, KK | 1 |
| Wareham, D | 2 |
| Parsons, B | 1 |
| Tive, L | 1 |
| Huang, S | 1 |
| Douglas, MW | 1 |
| Cunningham, AL | 1 |
| Criscuolo, S | 2 |
| Auletta, C | 2 |
| Lippi, S | 2 |
| Brogi, F | 2 |
| Brogi, A | 2 |
| Frampton, JE | 1 |
| Foster, RH | 1 |
| Watson, CP | 1 |
| Jean, WH | 1 |
| Wu, CC | 1 |
| Mok, MS | 1 |
| Sun, WZ | 1 |
| Tenser, RB | 1 |
| Berry, JD | 1 |
| Garry, EM | 1 |
| Delaney, A | 1 |
| Anderson, HA | 1 |
| Sirinathsinghji, EC | 1 |
| Clapp, RH | 1 |
| Martin, WJ | 1 |
| Krah, DL | 1 |
| Abbadie, C | 1 |
| Fleetwood-Walker, SM | 1 |
| Zareba, G | 1 |
| Moulin, D | 1 |
| Rodríguez, MJ | 1 |
| Díaz, S | 1 |
| Vera-Llonch, M | 1 |
| Rejas, J | 1 |
| Niscola, P | 1 |
| Perrotti, AP | 1 |
| del Poeta, G | 1 |
| Romani, C | 1 |
| Palombi, M | 1 |
| Piccioni, D | 1 |
| Scaramucci, L | 1 |
| Tolu, B | 1 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Abruzzese, E | 1 |
| D'Elia, GM | 1 |
| Brunetti, GA | 1 |
| Maurillo, L | 1 |
| Giovannini, M | 1 |
| Cartoni, C | 1 |
| de Fabritiis, P | 1 |
| Laville, MA | 1 |
| de la Gastine, B | 1 |
| Husson, B | 1 |
| Le Boisselier, R | 1 |
| Mosquet, B | 1 |
| Coquerel, A | 1 |
| Segal, AZ | 1 |
| Rordorf, G | 1 |
| Merren, MD | 1 |
| Rowbotham, M | 1 |
| Harden, N | 1 |
| Stacey, B | 1 |
| Bernstein, P | 1 |
| Magnus-Miller, L | 1 |
| Low, PA | 1 |
| Dotson, RM | 1 |
| Colman, E | 1 |
| Stadel, BV | 1 |
| Marples, IL | 1 |
| Murray, P | 1 |
| Beydoun, A | 1 |
| Carver, A | 1 |
| Payne, R | 1 |
| Foley, K | 1 |
| Block, F | 1 |
| Rice, ASC | 1 |
| Maton, S | 1 |
| Bowsher, D | 1 |
| Gehling, M | 1 |
| Tryba, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Electroacupuncture Therapy in Patients With Postherpetic Neuralgia: a Multicentre Randomised Controlled Trial[NCT04594226] | 132 participants (Actual) | Interventional | 2020-11-11 | Completed | |||
| Prophylactic Duloxetine Administration During Acute Herpes Zoster Prevents Postherpetic Neuralgia[NCT04313335] | 750 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | |||
| Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia[NCT03120962] | 140 participants (Anticipated) | Interventional | 2017-05-31 | Not yet recruiting | |||
| Analgetic Effectiveness of Acupuncture When Compared to a Standardised Analgesic Regimen in the Treatment of Herpes Zoster Neuralgia[NCT00885586] | Phase 4 | 68 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| The Efficacy and Safety of Intradermal Acupuncture for Acute Herpes Zoster: Study Protocol for a Randomized Controlled Trial[NCT05348382] | 72 participants (Anticipated) | Interventional | 2022-07-04 | Recruiting | |||
| Placebo-Controlled Study of Pregabalin for the Pain of Acute Herpes Zoster[NCT00352651] | Phase 2 | 34 participants (Anticipated) | Interventional | 2006-06-30 | Terminated (stopped due to "This study should be terminated as the study has been closed for years and the investigator has since retired. No records are available.~Thank you, Marlene") | ||
| [NCT01250561] | 133 participants (Actual) | Interventional | 2002-02-28 | Completed | |||
| Use of Single Dose Pre-Operative Pregabalin for Post-Operative Analgesia in Bilateral Head and Neck Cancer Surgery: A Randomized, Double-Blinded, Placebo-Controlled Trial[NCT03714867] | Phase 4 | 0 participants (Actual) | Interventional | 2019-03-22 | Withdrawn (stopped due to Inability to recruit patients) | ||
| Randomized Phase II Trial Evaluating Activity and Tolerability of Fixed Dose of Oxycodone and Increasing Dose of Pregabalin Versus Increasing Dose of Oxycodone and Fixed Dose of Pregabalin for the Treatment of Oncological Neuropathic Pain[NCT00637975] | Phase 2 | 80 participants (Anticipated) | Interventional | 2007-09-30 | Completed | ||
| Comparison of Oral Lamotrigine Versus Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy: Controlled Double-blind Study[NCT03419949] | 0 participants | Expanded Access | Available | ||||
| Pharmacokinetic Non-interaction Study Between Pregabalin 150 mg and Tramadol 50 mg, Administered Individually or in Combination, Single Dose in Healthy Subjects of Both Genders Under Fasting Conditions[NCT05389150] | Phase 1 | 30 participants (Actual) | Interventional | 2019-01-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
24 reviews available for gamma-aminobutyric acid and Herpes Zoster
| Article | Year |
|---|---|
γ-Aminobutyric Acid and Derivatives Reduce the Incidence of Acute Pain after Herpes Zoster - A Systematic Review and Meta-analysis.
Topics: Acute Pain; gamma-Aminobutyric Acid; Herpes Zoster; Humans; Incidence | 2020 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
Clinical practice. Postherpetic neuralgia.
Topics: Administration, Topical; Aged; Amines; Analgesics, Opioid; Anesthetics, Local; Antipyretics; Capsaic | 2014 |
[Pharmacology profile and clinical findings of pregabalin (Lyrica capsule)].
Topics: Analgesics; Animals; gamma-Aminobutyric Acid; Herpes Zoster; Humans; Mice; Neuralgia; Pain, Postoper | 2010 |
[Development of animal models of herpetic pain and postherpetic neuralgia and elucidation of the mechanisms of the onset and inhibition of allodynia].
Topics: Amines; Analgesics; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Cyclooxygenase Inhibitors | 2011 |
Chronic pain perspectives: Treating herpes zoster and postherpetic neuralgia: an evidence-based approach.
Topics: Amines; Analgesics; Analgesics, Opioid; Antidepressive Agents, Tricyclic; Antipruritics; Capsaicin; | 2012 |
Treatment and prevention of postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Drug Therapy, Combina | 2003 |
The role of gabapentin in treating diseases with cutaneous manifestations and pain.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
The use of gabapentin for the treatment of postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Drug Interactio | 2003 |
Gabapentin: in postherpetic neuralgia.
Topics: Acetates; Amines; Animals; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herpes | 2003 |
Gabapentin: a viewpoint by Brett R. Stacey.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herpes Zoster; H | 2003 |
Use of gabapentin for postherpetic neuralgia: results of two randomized, placebo-controlled studies.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2003 |
Diagnosis and management of neuropathic pain: a balanced approach to treatment.
Topics: Acetates; Amines; Antidepressive Agents; Chronic Disease; Cyclohexanecarboxylic Acids; Gabapentin; g | 2003 |
Post-herpetic neuralgia case study: optimizing pain control.
Topics: Acetates; Aged; Amines; Amitriptyline; Analgesics; Antidepressive Agents, Tricyclic; Cyclohexanecarb | 2004 |
80-year-old man with fever and ear pain.
Topics: Acetates; Acyclovir; Age Factors; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyc | 2004 |
Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Acupuncture Analgesia; Administration, Cutaneous; Amines; Analgesics; Analgesics, Opioid; Anti-Infla | 2004 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Adrenal Cortex Hormones; Adult; Amines; Amitriptyline; Analgesics, Non-Nar | 2003 |
Gabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dizziness; Dose-Response Relationship, Drug; | 2004 |
Tolerability of treatments for postherpetic neuralgia.
Topics: Amines; Anticonvulsants; Antidepressive Agents, Tricyclic; Cyclohexanecarboxylic Acids; Gabapentin; | 2004 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Pregabalin: in the treatment of postherpetic neuralgia.
Topics: gamma-Aminobutyric Acid; Herpes Zoster; Humans; Neuralgia; Pregabalin | 2005 |
Management issues of neuropathic trigeminal pain from a medical perspective.
Topics: Amines; Analgesics, Non-Narcotic; Anticonvulsants; Antidepressive Agents; Baclofen; Carbamazepine; C | 2004 |
Postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Amines; Antidepressive Agents, Tricyclic; Antiviral Agents; Arabinofuranos | 2004 |
Pregabalin: a new agent for the treatment of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Anti-Anxiety Agents; Anticonvulsants; Diabetic Neuropathies; Fibr | 2005 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
[Gabapentin therapy for pain].
Topics: Acetates; Amines; Analgesics; Clinical Trials as Topic; Cyclohexanecarboxylic Acids; Diabetic Neurop | 2001 |
16 trials available for gamma-aminobutyric acid and Herpes Zoster
| Article | Year |
|---|---|
Efficacy of low dose gabapentin in acute herpes zoster for preventing postherpetic neuralgia: a prospective controlled study.
Topics: Acetaminophen; Acyclovir; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Non-Narcotic; Ant | 2016 |
Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial.
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Clinical Protocols; Cyclohexanecarboxylic Acids; Do | 2017 |
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.
Topics: Acute Disease; Aged; Amines; Analgesics, Opioid; Clinical Trials as Topic; Cyclohexanecarboxylic Aci | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Acupuncture in acute herpes zoster pain therapy (ACUZoster) - design and protocol of a randomised controlled trial.
Topics: Acupuncture Therapy; Acute Disease; Adult; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxyli | 2009 |
Effects of pregabalin on acute herpetic pain and postherpetic neuralgia incidence.
Topics: Acute Disease; Adult; Aged; Analgesics; Double-Blind Method; Female; gamma-Aminobutyric Acid; Herpes | 2010 |
Effect of a single dose of pregabalin on herpes zoster pain.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; California; Cross-Over Studies; Do | 2011 |
Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial.
Topics: Adult; Affect; Aged; Analgesics, Non-Narcotic; Dizziness; Double-Blind Method; Edema; Female; gamma- | 2003 |
Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Dose-Response Relationship, D | 2004 |
Oxcarbazepine monotherapy in postherpetic neuralgia unresponsive to carbamazepine and gabapentin.
Topics: Adult; Aged; Aged, 80 and over; Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2005 |
Starting dose of gabapentin for patients with post-herpetic neuralgia--a dose-response study.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Dose-Response Relat | 2005 |
A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Anticonvulsants; Cross-Over Studi | 2005 |
Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Topics: Amines; Cost-Benefit Analysis; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Double-Blind Meth | 2007 |
Gabapentin for treatment of pain and tremor: a large case series.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Arachnoiditis; Cerebellar Neoplasms; Cyc | 1998 |
Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic | 1998 |
Postherpetic neuralgia: role of gabapentin and other treatment modalities.
Topics: Acetates; Administration, Topical; Age Factors; Aged; Ambulatory Care; Amines; Analgesics; Anticonvu | 1999 |
Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study.
Topics: Acetates; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Double-Bl | 2001 |
30 other studies available for gamma-aminobutyric acid and Herpes Zoster
| Article | Year |
|---|---|
Neurexin 3α in the Central Amygdala has a Role in Orofacial Varicella Zoster Pain.
Topics: Animals; Central Amygdaloid Nucleus; Chickenpox; Facial Pain; GABAergic Neurons; gamma-Aminobutyric | 2022 |
Can early administration of pregabalin reduce the incidence of postherpetic neuralgia?
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Female; gamma-Aminobutyric Acid; Herpes Zoster; Humans; | 2014 |
Decompensation of chronic heart failure associated with pregabalin in a 73-year-old patient with postherpetic neuralgia: a case report.
Topics: Aged; Anticonvulsants; Bumetanide; Chronic Disease; gamma-Aminobutyric Acid; Heart Failure; Herpes Z | 2008 |
Pregabalin as a probable cause of acute liver injury.
Topics: Acute Disease; Analgesics; Chemical and Drug Induced Liver Injury; gamma-Aminobutyric Acid; Herpes Z | 2008 |
Gabapentin-induced exacerbation of myasthenia gravis.
Topics: Aged; Amines; Cholinesterase Inhibitors; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagoni | 2010 |
The importance of early diagnosis of herpes zoster myelitis.
Topics: Acyclovir; Aged; Amines; Analgesics; Anti-Inflammatory Agents; Antiviral Agents; Cyclohexanecarboxyl | 2010 |
A case of post-herpetic itch resolved with gabapentin.
Topics: Adult; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Herpes Zost | 2011 |
Hip pain as initial presentation for varicella-zoster infection in an adolescent male.
Topics: Acyclovir; Adolescent; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Diagnosis, | 2011 |
Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study.
Topics: Acute Disease; Acyclovir; Aged; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; D | 2011 |
Prevent rather than treat postherpetic neuralgia by prescribing gabapentin earlier in patients with herpes zoster: comment on "incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes z
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Female; Gabapentin; ga | 2011 |
Gabapentin not shown to prevent postherpetic neuralgia.
Topics: Acyclovir; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Female; gamma-Aminobut | 2012 |
Varicella-zoster virus infection and nummular headache: a possible association with epicranial neuralgia.
Topics: 2-Aminopurine; Amines; Analgesics; Antiviral Agents; Comorbidity; Cyclohexanecarboxylic Acids; Famci | 2012 |
Patient pages. Treatment of postherpetic neuralgia.
Topics: Administration, Topical; Adult; Chickenpox; Chickenpox Vaccine; Child; gamma-Aminobutyric Acid; Gels | 2003 |
Treatment of post-herpetic pain in myasthenia gravis: exacerbation of weakness due to gabapentin.
Topics: Acetates; Amines; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Herpes Z | 2003 |
[Efficacy and tolerability of gabapentin in the treatment of patients with neuropathic pain. Results of an observational study involving 5620 patients].
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 2003 |
Change in opioid use after the initiation of gabapentin therapy in patients with postherpetic neuralgia.
Topics: Acetates; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Analgesics, Opioid; Cycloh | 2003 |
Treatment of postherpetic neuralgia.
Topics: 2-Aminopurine; Acyclovir; Age Factors; Aged; Amines; Analgesics; Analgesics, Opioid; Antidepressive | 2004 |
Oxcarbazepine (Trileptal) monotherapy dramatically improves quality of life in two patients with postherpetic neuralgia refractory to carbamazepine and gabapentin.
Topics: Aged; Amines; Analgesics, Non-Narcotic; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; | 2004 |
Herpes zoster and the prevention of postherpetic neuralgia: beyond antiviral therapy.
Topics: Amines; Analgesics, Opioid; Anticonvulsants; Antiviral Agents; Calcium Channels; Clinical Trials as | 2005 |
Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Cyclohexanecarboxylic Acids; Disease Models, Ani | 2005 |
Does acute pain associated with herpes zoster respond to treatment with gabapentin?
Topics: Acute Disease; Amines; Analgesics; Cross-Over Studies; Cyclohexanecarboxylic Acids; Double-Blind Met | 2006 |
Case reports: zoster pain in haematological malignancies: effective pain relief with oxycodone in patients unresponsive to other analgesic measures.
Topics: Acute Disease; Aged; Aged, 80 and over; Amines; Analgesics; Antiviral Agents; Cyclohexanecarboxylic | 2007 |
[Should we care about pregabalin for elderly patients with a history of cardiac dysrhythmia?].
Topics: Aged, 80 and over; Amines; Analgesics; Atrial Fibrillation; Cyclohexanecarboxylic Acids; Female; Gab | 2008 |
Gabapentin as a novel treatment for postherpetic neuralgia.
Topics: Acetates; Aged; Amines; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Amin | 1996 |
Symptomatic treatment of painful neuropathy.
Topics: Acetates; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; G | 1998 |
Gabapentin for postherpetic neuralgia.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 1999 |
Neuropathic pain.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Antiviral Agents; Cyclohexanecarboxylic Acids; Drug The | 1999 |
Herpes zoster.
Topics: Acetates; Acute Disease; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobut | 2000 |
Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study Group (UK), gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2002 |
Comment on Rice ASC, Maton S, the Postherpetic Neuralgia Study Group (UK), gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study.
Topics: Acetates; Amines; Analgesics; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; Herp | 2002 |